Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Moleculin Biotech, Inc.

MBRXNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 19, 2026Accepted Nov 19, 2026, 5:01 PM ESTFiling CIK 1659617Accession 0001437749-26-037748
Share

Structured filing — 4

rdgdoc.xml

Open full document ↗

Filing details

Report period
2026-11-17
Issuer
Moleculin Biotech, Inc.
Issuer CIK
0001659617
Trading symbol
MBRX

Reporting owner 1

Name
Climaco John M
Reporting owner CIK
0001546797
Relationship
Director
Address
C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON, TX, 77007

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Options (right to buy)6.832026-11-17A · Form 44,000A[F2][F1]2036-11-17Common Stock4,0004,334D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
The options set forth in this table vest on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date.↩ 1
F2
The options were issued in connection with the reporting person's Board of Director service to the Company.↩ 1

Signature 1

Signed
/s/ Jonathan Foster by Power of Attorney
Date
2026-11-19

Company context

We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 2/3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). We call this the “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation). A blinded preliminary data readout has been released for the MIRACLE trial, we released an interim unblinding of data in June 2026, and we expect an additional unblinding at the end of 2026, thereby concluding Part A of the two-part trial. We believe such early visibility for a pivotal registration-enabling trial is unique in that stakeholders will receive preliminary safety and efficacy data long before the conclusion of the trial.

Current securities

Recent company filings

  1. 4 filingNov 19, 2026
  2. 4 filingNov 19, 2026
  3. 4 filingNov 18, 2026
  4. 4 filingNov 18, 2026
  5. Regulation FD DisclosureNov 18, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.